does semaglutide help kidney function What are the risks of GLP-1s like Ozempic for CKD patients? Ozempic/Wegovy/Semaglutide has received US FDA

Bellwether Trials and Settlement Negotiations Strategic litigation milestones progressing toward resolution encompass: Case pool selection : Parties will nominate representative cases covering various injury types and severities from the 2,190 pending product liability lawsuits Bellwether discovery : Intensive case-specific discovery for selected plaintiffs including depositions and expert reports requiring months of preparation Trial selection process : Judge and parties choose 6-10 cases representing the broader litigation from diverse injury categories Sequential trials : Cases tried individually to gauge jury reactions and establish verdict ranges informing settlement values Settlement negotiations : Results inform global resolution discussions based on trial outcomes and liability findings Tiered compensation structure : Different settlement values for varying injury severities and evidence strength based on objective criteria Claims administration : Streamlined process for evaluating and paying individual settlements from global resolution funds Opt-out provisions : Plaintiffs retain rights to pursue individual trials if rejecting global settlement terms Based on typical pharmaceutical MDL timelines, bellwether trials in the Ozempic litigation likely wont begin before late 2026 or early 2027, following completion of general causation discovery and Daubert hearings on expert testimony admissibility

Personalized Assessment Before Treatment Your consultation helps identify risks before you begin

Casu, A

LeanMDs Muscle-First Approach Built for Every GLP-1 Medication Personalized protein targets based on your current lean body mass recalculated at every check-in Strength-focused movement plans introduced progressively as you lose weight Body composition monitoring tracking fat mass vs

Since patients with DM2 are already at increased risk for the development of arrhythmias, particularly atrial fibrillation, it is important to minimize therapies that will increase this risk